BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26130254)

  • 1. Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
    Lehmann TP; Korski K; Gryczka R; Ibbs M; Thieleman A; Grodecka-Gazdecka S; Jagodziński PP
    Mol Med Rep; 2015 Sep; 12(3):4692-4702. PubMed ID: 26130254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.
    Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ
    Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.
    Sakurai M; Masuda M; Miki Y; Hirakawa H; Suzuki T; Sasano H
    Int J Biol Markers; 2015 May; 30(2):e190-9. PubMed ID: 25907662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression.
    Eichelser C; Flesch-Janys D; Chang-Claude J; Pantel K; Schwarzenbach H
    Clin Chem; 2013 Oct; 59(10):1489-96. PubMed ID: 23748853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
    Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
    Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-4728-3p could act as a marker of HER2 status.
    Li H; Zhou X; Zhu J; Cheng W; Zhu W; Shu Y; Liu P
    Cancer Biomark; 2015; 15(6):807-14. PubMed ID: 26406406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
    McDermott AM; Miller N; Wall D; Martyn LM; Ball G; Sweeney KJ; Kerin MJ
    PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.
    Cascione L; Gasparini P; Lovat F; Carasi S; Pulvirenti A; Ferro A; Alder H; He G; Vecchione A; Croce CM; Shapiro CL; Huebner K
    PLoS One; 2013; 8(2):e55910. PubMed ID: 23405235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
    Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
    EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Underexpression of circulating miR-145-5p and miR-133a-3p are associated with breast cancer and immunohistochemical markers.
    García-Magallanes N; Beltran-Ontiveros SA; Leal-León EA; Luque-Ortega F; Romero-Quintana JG; Osuna-Ramirez I; Barbosa-Jasso M; Arámbula-Meraz E
    J Cancer Res Ther; 2020; 16(6):1223-1228. PubMed ID: 33342777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
    Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
    Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer.
    Li J; Song ZJ; Wang YY; Yin Y; Liu Y; Nan X
    Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential diagnostic role of circulating MiRNAs in breast cancer: Implications on clinicopathological characters.
    Swellam M; El Magdoub HM; Hassan NM; Hefny MM; Sobeih ME
    Clin Biochem; 2018 Jun; 56():47-54. PubMed ID: 29679553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of microRNAs-21/221 as potential breast cancer biomarkers in Egyptian women.
    Motawi TM; Sadik NA; Shaker OG; El Masry MR; Mohareb F
    Gene; 2016 Sep; 590(2):210-9. PubMed ID: 26827795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating microRNA-based screening tool for breast cancer.
    Frères P; Wenric S; Boukerroucha M; Fasquelle C; Thiry J; Bovy N; Struman I; Geurts P; Collignon J; Schroeder H; Kridelka F; Lifrange E; Jossa V; Bours V; Josse C; Jerusalem G
    Oncotarget; 2016 Feb; 7(5):5416-28. PubMed ID: 26734993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robust expression of tumor suppressor miRNA's let-7 and miR-195 detected in plasma of Saudi female breast cancer patients.
    Qattan A; Intabli H; Alkhayal W; Eltabache C; Tweigieri T; Amer SB
    BMC Cancer; 2017 Nov; 17(1):799. PubMed ID: 29183284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant plasma levels of circulating miR-16, miR-107, miR-130a and miR-146a are associated with lymph node metastasis and receptor status of breast cancer patients.
    Stückrath I; Rack B; Janni W; Jäger B; Pantel K; Schwarzenbach H
    Oncotarget; 2015 May; 6(15):13387-401. PubMed ID: 26033453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic Characteristics of Oestrogen Receptor-Positive/Progesterone Receptor-Negative/Her2-Negative Breast Cancer According to a Novel Definition of Negative Progesterone Receptor Status: A Large Population-Based Study from China.
    Li AQ; Zhou SL; Li M; Xu Y; Shui RH; Yu BH; Yang WT
    PLoS One; 2015; 10(5):e0125067. PubMed ID: 25938238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas.
    Regazzo G; Terrenato I; Spagnuolo M; Carosi M; Cognetti G; Cicchillitti L; Sperati F; Villani V; Carapella C; Piaggio G; Pelosi A; Rizzo MG
    J Exp Clin Cancer Res; 2016 Jul; 35(1):124. PubMed ID: 27476114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
    Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
    PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.